A safety review of CBD as an anti-inflammatory agent
CBD appears generally well-tolerated with anti-inflammatory potential, but safety data remains limited, especially for long-term use and drug interactions.
Quick Facts
What This Study Found
CBD has demonstrated anti-inflammatory properties across multiple preclinical and clinical contexts, with a safety profile that includes possible liver enzyme effects, drug interactions, and gastrointestinal symptoms at higher doses.
Key Numbers
The review covers multiple CBD administration modes and discusses safety signals including hepatotoxicity risk at high doses and interactions with cytochrome P450 enzymes.
How They Did This
Narrative review of published literature on CBD pharmacology, anti-inflammatory mechanisms, and safety data. Includes discussion of patents and various administration routes.
Why This Research Matters
CBD products are widely available and marketed for inflammation, but consumers and clinicians need clearer information about what safety data actually exists versus what is simply assumed.
The Bigger Picture
The gap between CBD market growth and rigorous safety research continues to widen. Most safety data comes from epilepsy trials using pharmaceutical-grade CBD at specific doses, which may not reflect the diverse products consumers actually use.
What This Study Doesn't Tell Us
Narrative review without systematic methodology. Does not include quantitative synthesis of safety data. Relies heavily on preclinical evidence. Published safety data skews toward pharmaceutical-grade CBD, not consumer products.
Questions This Raises
- ?What are the long-term safety outcomes for daily CBD use at common consumer doses?
- ?How do impurities and inconsistent potency in commercial CBD products affect the safety profile?
Trust & Context
- Key Stat:
- CBD safety data largely drawn from epilepsy trials, not consumer-grade products
- Evidence Grade:
- Narrative review without systematic search methodology. Provides useful overview but limited by lack of rigorous evidence synthesis.
- Study Age:
- Published 2022.
- Original Title:
- Current Cannabidiol Safety: A Review.
- Published In:
- Current drug safety, 18(4), 465-473 (2023)
- Authors:
- Singh, Chander, Rao, Komal, Yadav, Nikita, Vashist, Yogesh, Chugh, Palak, Bansal, Nidhi, Minocha, Neha
- Database ID:
- RTHC-04946
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Is CBD safe to use?
CBD is generally well-tolerated in most people. However, it can cause side effects including fatigue, diarrhea, and changes in appetite. At higher doses, liver enzyme elevations have been reported. CBD also interacts with several medications through cytochrome P450 pathways.
Can CBD reduce inflammation?
Preclinical research shows CBD has anti-inflammatory properties through multiple mechanisms. Clinical evidence is more limited, with most human data coming from studies on specific conditions like epilepsy rather than inflammation directly.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-04946APA
Singh, Chander; Rao, Komal; Yadav, Nikita; Vashist, Yogesh; Chugh, Palak; Bansal, Nidhi; Minocha, Neha. (2023). Current Cannabidiol Safety: A Review.. Current drug safety, 18(4), 465-473. https://doi.org/10.2174/1574886317666220902100511
MLA
Singh, Chander, et al. "Current Cannabidiol Safety: A Review.." Current drug safety, 2023. https://doi.org/10.2174/1574886317666220902100511
RethinkTHC
RethinkTHC Research Database. "Current Cannabidiol Safety: A Review." RTHC-04946. Retrieved from https://rethinkthc.com/research/singh-2023-current-cannabidiol-safety-a
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.